J&J Seeks U.S. and EU Approval of DARZALEX FASPRO®/DARZALEX® for High-Risk Smoldering Multiple Myeloma
Johnson & Johnson announced the submission of regulatory applications to the FDA and European Medicines Agency (EMA) seeking approval of a new indication for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in the U.S. and DARZALEX® subcutaneous ( …